1. Home
  2. COLL vs FNA Comparison

COLL vs FNA Comparison

Compare COLL & FNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • FNA
  • Stock Information
  • Founded
  • COLL 2002
  • FNA 2010
  • Country
  • COLL United States
  • FNA United States
  • Employees
  • COLL N/A
  • FNA N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • COLL Health Care
  • FNA Health Care
  • Exchange
  • COLL Nasdaq
  • FNA Nasdaq
  • Market Cap
  • COLL 1.1B
  • FNA 852.1M
  • IPO Year
  • COLL 2015
  • FNA 2021
  • Fundamental
  • Price
  • COLL $31.09
  • FNA $10.95
  • Analyst Decision
  • COLL Strong Buy
  • FNA Strong Buy
  • Analyst Count
  • COLL 6
  • FNA 5
  • Target Price
  • COLL $42.00
  • FNA $15.60
  • AVG Volume (30 Days)
  • COLL 439.3K
  • FNA 550.3K
  • Earning Date
  • COLL 11-07-2024
  • FNA 11-12-2024
  • Dividend Yield
  • COLL N/A
  • FNA N/A
  • EPS Growth
  • COLL 757.11
  • FNA N/A
  • EPS
  • COLL 2.16
  • FNA N/A
  • Revenue
  • COLL $599,245,000.00
  • FNA $244,995,000.00
  • Revenue This Year
  • COLL $13.20
  • FNA $18.58
  • Revenue Next Year
  • COLL $17.63
  • FNA $14.85
  • P/E Ratio
  • COLL $14.32
  • FNA N/A
  • Revenue Growth
  • COLL 9.62
  • FNA 18.16
  • 52 Week Low
  • COLL $28.97
  • FNA $4.65
  • 52 Week High
  • COLL $42.29
  • FNA $14.79
  • Technical
  • Relative Strength Index (RSI)
  • COLL 48.70
  • FNA 60.03
  • Support Level
  • COLL $29.67
  • FNA $10.19
  • Resistance Level
  • COLL $31.10
  • FNA $11.00
  • Average True Range (ATR)
  • COLL 0.98
  • FNA 0.51
  • MACD
  • COLL 0.26
  • FNA -0.13
  • Stochastic Oscillator
  • COLL 69.41
  • FNA 43.20

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About FNA Paragon 28 Inc.

Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.

Share on Social Networks: